• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by IDEAYA Biosciences Inc.

    6/9/25 4:10:16 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IDYA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    IDEAYA Biosciences, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    45166A102

    (CUSIP Number)


    06/06/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    45166A102


    1Names of Reporting Persons

    Point72 Asset Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,412,432.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,412,432.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,412,432.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    45166A102


    1Names of Reporting Persons

    Point72 Capital Advisors, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,412,432.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,412,432.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,412,432.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    45166A102


    1Names of Reporting Persons

    Steven A. Cohen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,412,432.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,412,432.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,412,432.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    IDEAYA Biosciences, Inc.
    (b)Address of issuer's principal executive offices:

    5000 Shoreline CT, Suite 300, South San Francisco, CA 94080
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.0001 per share ("Shares"), of IDEAYA Biosciences, Inc. held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to Shares held by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. Each of Cubist Systematic Strategies, LLC and Point72 Asia (Singapore) Pte. Ltd. are advisors under common control with Point72 Asset Management, and each acts as a sub-advisor with respect to a portion of the Shares reported herein. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
    (c)Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    45166A102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 6, 2025. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.
    (b)Percent of class:

    5.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 6, 2025.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 6, 2025.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 6, 2025.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 6, 2025

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Point72 Asset Management, L.P.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:06/09/2025
     
    Point72 Capital Advisors, Inc.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:06/09/2025
     
    Steven A. Cohen
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:06/09/2025
    Exhibit Information

    Exhibit 99.1: Joint Filing Agreement

    Get the next $IDYA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IDYA

    DatePrice TargetRatingAnalyst
    6/26/2025$44.00Overweight
    Wells Fargo
    11/18/2024$51.00Overweight
    Stephens
    11/5/2024$27.00Outperform → Market Perform
    Leerink Partners
    10/24/2024$50.00Buy
    UBS
    10/15/2024Overweight
    Cantor Fitzgerald
    7/8/2024$50.00Outperform
    Mizuho
    3/8/2024$55.00Buy
    BTIG Research
    8/8/2023$33.00Outperform
    SVB Securities
    More analyst ratings

    $IDYA
    SEC Filings

    See more
    • SEC Form 8-K filed by IDEAYA Biosciences Inc.

      8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)

      6/27/25 4:06:26 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by IDEAYA Biosciences Inc.

      8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)

      6/24/25 5:27:03 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by IDEAYA Biosciences Inc.

      SCHEDULE 13G - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      6/9/25 4:10:16 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., June 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 26, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 95,600 shares of the Company's common stock to a newly hired employee. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individual entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 563

      6/27/25 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

      SOUTH SAN FRANCISCO, Calif., June 2, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. 2025 Jefferies Global Healthcare ConferenceWednesday, June 4th, 2025 at 8:10 AM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, BiotechnologyGoldman Sachs 46th Annual Global Healthcare Conference 2025Monday, June 9th, 202

      6/2/25 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., May 30, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 29, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 664,600 shares of the Company's common stock to nine newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rul

      5/30/25 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on IDEAYA Biosciences with a new price target

      Wells Fargo initiated coverage of IDEAYA Biosciences with a rating of Overweight and set a new price target of $44.00

      6/26/25 8:10:34 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on IDEAYA Biosciences with a new price target

      Stephens initiated coverage of IDEAYA Biosciences with a rating of Overweight and set a new price target of $51.00

      11/18/24 8:39:33 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded IDEAYA Biosciences from Outperform to Market Perform and set a new price target of $27.00

      11/5/24 7:22:44 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Bleharski Joshua

      3 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

      6/27/25 4:20:15 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Yarno Wendy L

      4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

      6/26/25 4:57:37 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Stein Jeffrey

      4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

      6/26/25 4:56:47 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Financials

    Live finance-specific insights

    See more
    • IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

      Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with >30% tumor shrinkage by product of diameters, and ~61% eye preservation rate for enucleation patientsTargeting to initiate Phase 3 randomized registrational trial in neoadjuvant UM following finalization of the clinical protocol with FDAClinical endpoints supportive of full approval based on FDA guidance: Eye preservation rate as the primary endpoint for enucleation patients. Time to vision loss as the primary endpoint for plaque brachytherapy patients. No detriment to Event-Free-Survival (EFS) in the treatment arms is a secondary endpointDiscuss

      9/23/24 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

      SOUTH SAN FRANCISCO, Calif., Sept. 22, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM). Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being developed to broadly address primary and metastatic UM.

      9/22/24 9:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

      ~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC patients~94% Disease Control Rate (DCR): 1 CR and 6 PRs and 10 SD by RECIST 1.1~78% of Patients with Tumor Shrinkage: 14 patients observed tumor shrinkage~81% ctDNA Molecular Response Rate (MRR): 13 of 16 patients with > 50% ctDNA reductionAE Profile: ~5.6% drug-related grade >3 AEs and no drug-related SAEs or discontinuations at 30 mg once-a-day expansion doseIDE397 expansion dose of 30 mg once-a-day achieved target drug coverage and plasma SAM pharmacodynamic reduction associated with preclinical tumor regressions~48k U.S. annual incidence of MTAP-

      7/8/24 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Leadership Updates

    Live Leadership Updates

    See more
    • IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Joshua Bleharski, Ph.D. as Chief Financial Officer.  Dr. Bleharski joins IDEAYA from J.P. Morgan, where he spent nearly 17 years advising clients in the biopharma sector on capital markets transactions, corporate strategy and other investment banking services. IDEAYA anticipates that Dr. Bleharski will complete the transition into his new role by early May. 

      2/10/25 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

      Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial launches for products including Trodelvy® and Opdivo®SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Stu Dorman as Chief Commercial Officer. Mr. Dorman has a track record of commercial success in numerous specialty disease areas with over 20 years of oncology and hematology experience.

      11/18/24 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

      Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

      9/18/24 6:00:00 AM ET
      $IDYA
      $GWPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $IDYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

      SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      11/14/24 4:23:02 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

      SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      11/14/24 3:13:37 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

      SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      11/14/24 1:22:38 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care